Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations identifier:
NCT03990896 (


Study Contact Information:

The study principal investigator, Dr. Neelima Vidula can be contacted at 617-726-6500.

The overall study coordinator, Erin Basile can be contacted at 617-724-5059.

About the Study

This is a study for patients with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for people with an inherited BRCA1/2 mutation) is effective in this population.

Type of Study

This is a phase 2, open-label, single arm, multi-center clinical trial evaluating talazoparib in patients with metastatic breast cancer who have somatic BRCA1/2 mutations detectable in cell-free DNA. Patients with triple-negative (TNBC) or hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer are eligible. Patients are treated with talazoparib until disease progression, unacceptable toxicity, or withdrawal of consent.

What the Study Entails

Study Sites

This Study is Open To:

Patients may participate if they have the following:

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.